Mingke Pharmaceutical: 79.5235 million restricted shares from the initial public offering will be listed and traded on January 5th, 2026.

Mingke Pharmaceuticals announced that this restricted shares being listed for the first time are part of the pre-public offering, totaling 79.5235 million shares, accounting for 12.13% of the total share capital of the company, involving three shareholders, including GeniePharma, Mingke Hong Kong, and Xin Yioumai. These restricted shares will be listed for trading starting on January 5, 2026. Since the company went public, the total number of shares has increased from 655,210,084 to 655,605,491 due to the implementation of the 2023 restricted stock incentive plan. The sponsor institution has no objections to the lifting of restrictions on the trading of these restricted shares.